GlassScriptPhysician profile
Kenneth J Stallman
NPI 1871575100
$5,487.59
in general payments reported to CMS, 2019-2025
17 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $41.52 · 2021: $142 · 2022: $110 · 2023: $281 · 2024: $3,715 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $878 · Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $877.70 |
| Food and Beverage | $446.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,723.21 | 2019-2024 | Da Vinci Surgical System |
| Sn Holdings, LLC | $142.00 | 2021 | |
| Profound Medical Corp. | $141.10 | 2025 | Tulsa-Pro |
| Biotissue Holdings INC. | $109.64 | 2022 | |
| Angiodynamics, INC. | $73.93 | 2025 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $61.98 | 2025 | |
| Blue Earth Diagnostics | $54.23 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $51.20 | 2025 | Gemtesa |
| Dornier Medtech America, INC | $41.52 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $29.21 | 2024 | Lynparza |
| Dendreon Pharmaceuticals LLC | $22.92 | 2019 | |
| Antares Pharma, INC. | $19.24 | 2019 | |
| Mission Pharmacal Company | $17.41 | 2024 | Uribel Tabs |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Stallman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.